Murray Dallan 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Murray Dallan
Chief Customer Officer
Transactions
- Tax Payment
Common Stock
2025-03-10$100.13/sh−996$99,729→ 32,663 total - Exercise/Conversion
Performance Stock Units
2025-03-07−5,500→ 0 total→ Common Stock (5,500 underlying) - Exercise/Conversion
Common Stock
2025-03-07+5,500→ 33,659 total - Tax Payment
Common Stock
2025-03-10$100.13/sh−2,737$274,056→ 29,926 total - Award
Common Stock
2025-03-10+8,276→ 38,202 total - Award
Stock Options (right to buy)
2025-03-10+16,644→ 16,644 totalExercise: $99.69From: 2026-03-10Exp: 2035-03-10→ Common Stock (16,644 underlying)
Footnotes (5)
- [F1]Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.
- [F2]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
- [F3]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022.
- [F4]The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
- [F5]Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.